BRPI0608175A2 - método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides - Google Patents

método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides

Info

Publication number
BRPI0608175A2
BRPI0608175A2 BRPI0608175-4A BRPI0608175A BRPI0608175A2 BR PI0608175 A2 BRPI0608175 A2 BR PI0608175A2 BR PI0608175 A BRPI0608175 A BR PI0608175A BR PI0608175 A2 BRPI0608175 A2 BR PI0608175A2
Authority
BR
Brazil
Prior art keywords
tumors
cell population
cells
heterogeneous
eliminating
Prior art date
Application number
BRPI0608175-4A
Other languages
English (en)
Inventor
Viktor S Goldmakher
Yelena V Kovtun
John M Lambert
Hans K Erickson
Robert J Lutz
Ravi V J Chari
Rita Steeves
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of BRPI0608175A2 publication Critical patent/BRPI0608175A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

METODO DE ELIMINAçãO DE POPULAçãO DE CéLULAS HETEROGêNEAS OU MISTAS EM TUMORES, ASSIM COMO COMPOSTOS MAITANSINóIDES. A presente invenção refere-se aos métodos de extermínio ou inibição de tumores compreendendo populações de célula heterogêneas ou mistas. O extermínio ou a inibição de tumores é atingido através do direcionamento seletivo de um liginte específico suspeito de ser expresso em uma determinada população de células e também para exterminar uma população de células que estejam em falta de tal ligante específico. Esses conjugados têm uso terapêutico já que eles são liberados para uma população específica de células para exterminar essas células e a droga citotóxica é liberada para exterminar as células não-alvejadas, eliminando desse modo o tumor.
BRPI0608175-4A 2005-04-15 2006-04-14 método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides BRPI0608175A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67149805P 2005-04-15 2005-04-15
US78172206P 2006-03-14 2006-03-14
PCT/US2006/014411 WO2006113623A2 (en) 2005-04-15 2006-04-14 Elimination of heterogeneous or mixed cell population in tumors

Publications (1)

Publication Number Publication Date
BRPI0608175A2 true BRPI0608175A2 (pt) 2009-11-10

Family

ID=37115818

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608175-4A BRPI0608175A2 (pt) 2005-04-15 2006-04-14 método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides

Country Status (14)

Country Link
US (3) US20060233814A1 (pt)
EP (1) EP1868649A4 (pt)
JP (1) JP2008538365A (pt)
KR (1) KR20070120156A (pt)
CN (1) CN102603770A (pt)
AU (1) AU2006236489C1 (pt)
BR (1) BRPI0608175A2 (pt)
CA (1) CA2618721A1 (pt)
CR (1) CR9518A (pt)
EA (1) EA200702239A1 (pt)
IL (1) IL186535A (pt)
MX (1) MX2007012817A (pt)
NO (1) NO20075245L (pt)
WO (1) WO2006113623A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1506286B1 (en) * 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
ZA200503075B (en) * 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
CA2524305C (en) * 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
PT1828249E (pt) * 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
ES2503719T3 (es) * 2005-02-11 2014-10-07 Immunogen, Inc. Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
CA2612449A1 (en) * 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
CA3000520C (en) 2005-08-24 2023-04-04 Immunogen, Inc. Process for preparing antibody maytansinoid conjugates
NZ566395A (en) * 2005-09-26 2012-03-30 Medarex Inc Human monoclonal antibodies to CD70
AP2008004569A0 (en) * 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
RU2495882C2 (ru) * 2006-09-08 2013-10-20 Медиммун, Ллк. Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
MX2009006277A (es) * 2006-12-14 2009-07-24 Medarex Inc Anticuerpos humanos que se enlazan a cd70 y usos de los mismos.
CN101965366B (zh) * 2007-12-26 2016-04-27 生物测试股份公司 靶向cd138的免疫缀合物及其应用
WO2009080831A1 (en) * 2007-12-26 2009-07-02 Biotest Ag Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
US9221914B2 (en) 2007-12-26 2015-12-29 Biotest Ag Agents targeting CD138 and uses thereof
WO2009080832A1 (en) 2007-12-26 2009-07-02 Biotest Ag Methods and agents for improving targeting of cd138 expressing tumor cells
AU2009234373B2 (en) * 2008-04-09 2015-09-24 Cornell University Coferons and methods of making and using them
NZ610239A (en) * 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
AU2015202204A1 (en) * 2008-04-30 2015-05-14 Immunogen, Inc. Cross-linkers and their uses
SG10201810743WA (en) 2009-06-03 2018-12-28 Immunogen Inc Conjugation methods
CA2774476A1 (en) 2009-10-07 2011-04-14 Francis Barany Coferons and methods of making and using them
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
EA201390575A1 (ru) 2010-10-29 2014-01-30 Иммьюноджен, Инк. Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
EA201390472A1 (ru) 2010-10-29 2014-02-28 Иммьюноджен, Инк. Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты
ME03353B (me) 2011-03-29 2019-10-20 Immunogen Inc Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
JP6209159B2 (ja) * 2011-06-21 2017-10-04 イミュノジェン・インコーポレーテッド ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
AU2015224535B2 (en) * 2011-06-21 2017-07-20 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
CA2856411A1 (en) 2011-11-21 2013-05-30 Immunogen, Inc. Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
KR20140100571A (ko) 2011-12-08 2014-08-14 바이오테스트 아게 Ｃｄ１３８을 타겟팅하는 면역접합체의 용도
RU2661083C2 (ru) 2012-10-04 2018-07-11 Иммуноджен, Инк. Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
CN105997942B (zh) * 2016-06-24 2019-01-29 浙江大学 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用
MX2021006557A (es) 2018-12-04 2021-09-08 Der Yang Tien Estereocomplejos para la administración de agentes anticancerígenos.
US11555019B2 (en) 2019-07-10 2023-01-17 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
MX2022000449A (es) 2019-07-10 2022-04-25 Cybrexa 2 Inc Conjugados peptídicos de citotoxinas como terapéuticos.
WO2022010797A2 (en) 2020-07-07 2022-01-13 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
CN1816356A (zh) * 2003-05-14 2006-08-09 免疫原公司 药物缀合物组合物
US7276497B2 (en) * 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
MXPA05011811A (es) * 2003-05-20 2006-02-17 Immunogen Inc Agentes citotoxicos mejorados que comprenden nuevos maitansinoides.

Also Published As

Publication number Publication date
CN102603770A (zh) 2012-07-25
WO2006113623A2 (en) 2006-10-26
EP1868649A4 (en) 2011-06-29
MX2007012817A (es) 2007-12-12
US8137669B2 (en) 2012-03-20
EP1868649A2 (en) 2007-12-26
CA2618721A1 (en) 2006-10-26
US8388960B2 (en) 2013-03-05
US20110319612A1 (en) 2011-12-29
NO20075245L (no) 2008-01-14
KR20070120156A (ko) 2007-12-21
JP2008538365A (ja) 2008-10-23
IL186535A0 (en) 2008-01-20
US20060233814A1 (en) 2006-10-19
US20090076263A1 (en) 2009-03-19
AU2006236489B2 (en) 2010-10-28
AU2006236489C1 (en) 2012-04-12
WO2006113623A3 (en) 2008-09-12
AU2006236489A1 (en) 2006-10-26
EA200702239A1 (ru) 2008-10-30
AU2006236489A2 (en) 2006-10-26
IL186535A (en) 2012-03-29
CR9518A (es) 2008-08-11

Similar Documents

Publication Publication Date Title
BRPI0608175A2 (pt) método de eliminação de população de células heterogêneas ou mistas em tumores, assim como compostos maitansinóides
Kunnumakkara et al. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins
WO2006020722A3 (en) Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
EA201390642A1 (ru) Цитотоксические агенты, содержащие новые производные анзамитоцина
ZA202004099B (en) Methylene carbamate linkers for use with targeted-drug conjugates
MX2007010996A (es) Nuevas composiciones de liposomas.
MX2010006739A (es) Compuestos pirido[2,3-b]pirazina-8-sustituidos y su uso.
NZ626867A (en) Compositions and methods for the treatment of infections and tumors
WO2007147128A3 (en) Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
CL2011000119A1 (es) Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
UY28271A1 (es) Compuestos químicos
EA201691053A1 (ru) Соединения к рецептору фактора роста фибробластов 3 типа (fgfr3) и способы терапии
ATE527998T1 (de) Illudin-analoga als krebsmittel
ZA202207211B (en) Peptide docking vehicle for targeted nucleic acid delivery
Mahato et al. Plant-based natural products in cancer therapeutics
WO2005065361A3 (en) Compounds and compositions for treating dysproliferative diseases, and methods of use thereof
MXPA05010575A (es) Peptacuerpo para el tratamiento del cancer.
WO2007084625A3 (en) Novel compounds and methods for inhibiting p53 activity
MX2009009533A (es) Conjugados de hidroxipolimero modificado con efecto letal en celulas tumorales.
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: IMMUNOGEN, INC. (US)

Free format text: ENDERECO DO DEPOSITANTE ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110101858/RJ DE 30/09/2011.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.